Injection treatment for stubborn nodular prurigo
Treatments studied
Part of Skin clinical trials.
This trial tests if a combination injection of two drugs (5-fluorouracil and triamcinolone) can clear stubborn nodules that haven't responded to other treatments. It may help people with long-lasting, itchy bumps that are hard to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had nodular prurigo (itchy bumps) for at least 6 months
- You have 10 to 12 symmetrically distributed bumps on your trunk or limbs
- You have tried other treatments (like antihistamines or special medications) but they only partly helped
- You haven't had this specific injection in the past 12 weeks
- You are between 18 and 70 years old
- You agree to use birth control if needed during the trial and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This study tests whether a drug called lebrikizumab can reduce severe itching and skin bumps caused by prurigo nodularis (a chronic skin condition). The drug works by calming an overactive immune response in the skin.
Hear when a new Nodular Prurigo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.